Delivery Order HHSN261201500018I-75N91018F00009
Award Date
9/17/18
Potential Completion Date
12/16/22
Potential Value
$849K
Federal Agency
National Cancer Institute
Ultimate Awardee
University Of Texas System
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract is part of the PREVENT Cancer Program, a preclinical research initiative focused on developing prevention strategies for breast cancer. The $714,123.60 contract supports "TARGETING THE MTOR PATHWAY FOR THE PREVENTION OF...
The National Cancer Institute awarded a Firm Fixed Price Delivery Order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, valued at $1,121,090.00. The contract is part of the PREVENT Preclinical Drug Development Program and supports preclinical efficacy and intermediate endpoint biomarker studies targeting the PARP pathway for the prevention of breast cancer. The contract has a period of performance through May 31, 2026 and is not set...
This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
The National Cancer Institute (NCI) awarded a $2,067,521.23 delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct early phase clinical research for the Cancer Prevention Agent Development Program. This contract is a child under the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle. MD Anderson, as a comprehensive cancer research and treatment center, will provide various services in support of this cancer...
This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health's National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $1,219,899.79 firm fixed price contract supports cancer prevention research through vaccination against induced antigens, as part of the PREVENT Preclinical Drug Development Program. The contract does not have a set-aside designation. MD Anderson Cancer...
This is a delivery order issued under the National Cancer Institute's Cancer Prevention Agent Development Program 2012-2017 indefinite delivery/indefinite quantity (IDIQ) contract. The contract was awarded to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to provide core infrastructure support for the program. The award has a ceiling value of $725,737.89 and an ultimate completion date of September 23, 2015. The contract is a cost-no-fee type...
This is a Delivery Order issued against the National Institutes of Health's PREVENT Cancer Program (PREVENT) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, valued at $4,445.48, was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "CONTRACT ORIENTATION AND KICKOFF MEETING" related to the PRECLINICAL PREVENT CANCER PROGRAM initiative. The award has an ultimate completion date of December 31, 2015 and does...
This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a...
This is a three-year, $13,481,325.00 definitive contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract supports a Phase II chemoprevention clinical trial in patients with adenomatous polyposis coli, a genetic condition that increases cancer risk. The contract does not have a small business set-aside designation. MD Anderson Cancer Center, a comprehensive cancer research and...
This is a firm fixed-price delivery order contract awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "Targeted Casein Kinase Inhibition as a Breast Cancer Prevention" research project. The $505,743.00 contract, which has no set-aside designation, was awarded on June 20, 2017 and is scheduled for completion by December 31, 2019. The contract falls under...